Brief: Avalo Therapeutics Announces Completion Of Enrollment In Phase 2 LOTUS Trial Of AVTX-009 For The Treatment Of Hidradenitis Suppurativa
29/10/2025 11:04
Oct 29 (Reuters) - Avalo Therapeutics Inc AVTX.O: AVALO THERAPEUTICS ANNOUNCES COMPLETION OF ENROLLMENT IN PHASE 2 LOTUS TRIAL OF AVTX-009 FOR THE TREATMENT OF HIDRADENITIS SUPPURATIVA AVALO THERAPEUTICS - LOTUS TRIAL ENROLLS 250 PATIENTS, TOPLINE DATA FROM TRIAL IS EXPECTED IN MID-2026. Source text: ID:nGNX3m7XSc Further company coverage: AVTX.O